Effect of heparin on fibrinolytic activity and platelet function in vivo

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 271, Issue 2 40-2, 1996, Pages

  Upchurch, Gilbert R ^b   Valeri, C Robert ^b   Khuri, Shukri F ^b   Rohrer, Michael J ^b   Welch, George N ^b   Macgregor, Holly ^b   Ragno, Gina ^b   Francis, Stephanie ^b   Rodino, Louis J ^b   Michelson, Alan D ^b   Loscalzo, Joseph ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

fibrinolysis; glycosaminoglycans; P selectin; plasminogen activation

Indexed keywords

GLYCOSAMINOGLYCAN; HEPARIN; PADGEM PROTEIN; PLASMIN;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; FIBRINOLYSIS; HYPOTHERMIA; MALE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

EID: 33750716927     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1996.271.2.h528     Document Type: Article

References (41)

1. Adelman, B., A. D. Michelson, J. Loscalzo, J. Greenburg, and R. I. Handin. Plasmin effect on platelet glycoprotein Ib-von Willebrand Factor interactions. Blood 65: 32-40, 1985.
2. 2-macroglobulin, and antithrombin III in the presence of heparin. Thromb. Res. 59: 449-462, 1990.
3. Babson, S. R., and S. L. Babson. Development and evaluation of a disposable device for performing simultaneous duplicate bleeding time determinations. Am. J. Clin. Pathol. 70: 406-408, 1978.
4. Bevilacqua, M., E. Butcher, B. Furie, B. C. Furie, M. Gallatin, M. Gimbrone, J. Harlan, K. Kishimoto, L. Lasky, R. McEver, J. Paulson, S. Rosen, B. Seed, M. Siegelman, T. Springer, L. Stoolman, T. Tedder, A. Varki, D. Wagner, I. Weissman, and G. Zimmerman. Selecting: a family of adhesion receptors (Letter). Cell 67: 233, 1991.
5. Bidstrup, B. P., D. Royston, R. N. Sapsford, and K. M. Taylor. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin. J. Thorac. Cardiovasc. Surg. 97: 364-372, 1989.
6. Blauhut, B., C. Gross, S. Necek, J. E. Doran, P. Spath, and P. Ludsgaard-Hansen. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 101: 958-967, 1991.
7. Edmunds, L. H., Jr., N. Ellison, R. W. Colman, S. Niewiarowski, A. K. Rao, V. P. Addonizio, L. W. Stephenson, and R. N. Edie. Platelet function during cardiac operation: comparison of the membrane and bubble oxygenators. J. Thorac. Cardiovasc. Surg. 83: 805-812, 1982.
8. Eidt, J. F., P. Allison, S. Noble, J. Ashton, P. Golino, J. McNatt, L. M. Buja, and J. T. Willerson. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J. Clin. Invest. 84: 18-27, 1989.
9. Fareed, J., J. M. Walenga, D. A. Hoppensteadt, and H. L. Messmore. Studies on the profibrinolytic actions of heparin and its fractions. Semin. Thromb. Hemostasis 11: 199-207, 1985.
10. Gatter, K. C., J. L. Cordell, H. Turley, A. Heryet, N. Kieffer, D. J. Anstee, and D. Y. Mason. The immunohistological detection of platelets, megakaryocytes and thrombi in routinely processed specimens. Histopathology 13: 257-267, 1988.
11. Ghezzo, F., S. Romano, R. Mazzone, G. Gorzegno, and G. Emanuelli. Heparin neutralizes serum antiplasmin inhibition of peripheral blood leukocyte fibrinolytic activity. Thromb. Res. 46: 199-204, 1987.
12. Giuliani, R., E. Szwarcer, A. E. Martinez, and G. Palumbo. Fibrin-dependent fibrinolytic activity during extracorporeal circulation. Thromb. Res. 61: 369-373, 1991.
13. Halse, T. Aktieverung der Fibrinolyse and Thrombolyse durch Polysaccharide Schwefelsaeureester (heparin, heparinoide). Arzneim. Forsch. 12: 574, 1962.
14. Hanson, S. R., and L. A. Harker. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin Δ-phenylalanyl-L-prolyl-L-arginylchloromethylketone. Proc. Natl. Acad. Sci. USA 85: 3184-3188, 1988.
15. Harker, L. A. Bleeding after cardiopulmonary bypass. N. Engl. J. Med. 314: 1446-1448, 1986.
16. Harker, L. A., T. W. Malpass, H. E. Branson, E. A. Hessel, and S. J. Slichter. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective α-granule release. Blood 56: 824-834, 1980.
17. Hsu-Lin, S., C. L. Herman, B. C. Furie, D. August, and B. Furie. A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets. J. Biol. Chem. 259: 9121-9126, 1984.
18. Katagiri, Y., Y. Hayashi, K. Yamamoto, K. Tanoue, G. Kosaki, and H. Yamazaki. Localization of von Willebrand factor and thrombin-interactive domains on human platelet glycoprotein Ib. Thromb Haemostasia 63: 122-126, 1990.
19. Kelly, A. B., U. M. Marzec, W. Krupski, A. Bass, Y. Cadroy, S. R. Hanson, and L. A. Harker. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 77: 1006-1012, 1991.
20. Kestin, A. S., C. R. Valeri, S. F. Khuri, J. Loscalzo, P. A. Ellis, H. MacGregor, V. Birjiniuk, H. Ouimet, B. Pasche, M. J. Nelson, S. E. Benoit, L. J. Rodino, M. R. Barnard, and A. D. Michelson. The platelet function defect of cardiopulmonary bypass. Blood 82: 107-117, 1993.
21. Khuri, S. F., C. R. Valeri, J. Loscalzo, M. Weinstein, V. Birjiniuk, N. Healey, H. MacGregor, M. Doursounian, and M. Zolkewitz. Heparin causes platelet dysfunction and induces fibrinolysis before the institution of cardiopulmonary bypass. Ann. Thorac. Surg. 60: 1008-1014, 1995.
22. Khuri, S. F., J. A. Wolfe, M. Josa, T. C. Axford, I. Szymanski, S. Assousa, G. Ragno, M. Patel, A. Silverman, M. Park, and C. R. Valeri. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J. Thorac. Cardiovasc. Surg. 104: 94-107, 1992.
23. Kongsgaard, U. E., N. Smith-Erichsen, O. Geiran, and L. Bjirnskau. Changes in the coagulation and fibrinolytic systems during and after cardiopulmonary bypass surgery. J. Thorac. Cardiovasc. Surg. 37: 158-162, 1989.
24. Kowalski, E., M. Kopac, and U. Wegrzyowitz. Influence of fibrinogen degradation products (FDP) on platelet aggregation, adhesion, and viscous metamorphosis. Thromb. Diath. Haemorrh. 10: 406-413, 1963.
25. Mammen, E. F., M. H. Koets, B. C. Washington, L. W. Wolk, J. M. Brown, M. Burdick, N. R. Selik, and R. F. Wilson. Hemostasis changes during cardiopulmonary bypass surgery. Semin. Thromb. Hemostasis 11: 281-292, 1985.
26. Markwardt, F. K., and H. P. Blocking. Heparin-induced release of plasminogen activator. Haemostasis 6: 370-374, 1977.
27. Michelson, A. D., H. MacGregor, M. R. Barnard, A. S. Kestin, M. J. Rohrer, and C. R. Valeri. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb. Haemostasis 71: 633-640, 1994.
28. Orchard, M. A., C. S. Goodchild, C. R. M. Prentice, J. A. Davies, S. E. Benoit, L. J. Creighton-Kemsford, P. J. Gaffney, and A. D. Michelson. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br. J. Haematol. 85: 533-541, 1993.
29. Pasche, B., H. Ouimet, S. Francis, and J. Loscalzo. Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 83: 404-414, 1994.
30. Rijken, D. C., G. A. de Munk, and A. F. Jie. Interactions of plasminogen activators and plasminogen with heparin: effect of ionic strength. Thromb. Haemostasis 70: 867-872, 1993.
31. Rinder, C. S., J. P. Mathew, H. M. Rinder, J. Bonan, K. A. Ault, and B. R. Smith. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology 75: 563-570, 1991.
32. Schlossman, S. F., I. L. Boumsell, W. Gilks, J. M. Harlan, T. Kishimoto, C. Morimoto, J. Ritz, S. Shaw, R. L. Silverstein, T. A. Sprinter, T. F. Tedder, and R. F. Todd. CD antigens 1993. Blood 83: 879-880, 1994.
33. Stenberg, P. E., R. P. McEver, M. A. Shuman, Y. V. Jacques, and D. F. Bainton. A platelet alpha-granule membrane protein (GPM-140) is expressed on the plasma membrane after activation. J. Cell Biol. 101: 880-886, 1985.
34. Vairel, E. G., H. Bouty-Boye, F. Toulemonde, C. Doutremepuich, N. A. Marsh, and P. J. Gaffney. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb. Res. 30: 219-224, 1983.
35. Valeri, C. R., K. Khabbaz, S. F. Khuri, C. Marquardt, G. Ragno, H. Feingold, A. D. Gray, and T. Axford. Effect of skin temperature on platelet function in extracorporeal bypass patients. J. Thorac. Cardiovasc. Surg. 104: 108-116, 1992.
36. Vandenvelde, C., P. Fondu, and J. Dubois-Primo. Low-dose aprotinin for reduction of blood loss after cardiopulmonary bypass. Lancet 337: 1157-1158, 1991.
37. Vander Salm, T. J., J. E. Ansell, O. N. Okike, T. H. Marsicano, R. Lew, W. P. Stephenson, and K. Rooney. The role of ε-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. J. Thorac. Cardiovasc. Surg. 95: 538-540, 1988.
38. Van Oeveren, W., M. P. Harder, K. J. Roozendaal, L. Eijsman, and C. R. Wildevuur. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 99: 788-796, 1990.
39. Weitz, J. I., M. Hudoba, D. Massel, J. Maraganore, and J. Hirsh. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86: 385-391, 1990.
40. Wenger, R. K., H. Lukasiewicz, B. S. Mikuta, S. Niewiarowski, and L. H. Edmunds, Jr. Loss of platelet fibrinogen receptors during cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 97: 235-239, 1989.
41. Woodman, R. C., and L. A. Harker. Bleeding complications associated with cardiopulmonary bypass. Blood 76: 1680-1697, 1990.